Biotech Archives - Page 756 of 795

1 minute read

TELA Bio Earlier Highlighted Results From BRAVO And ReBAR Studies On The Benefits Of OviTex Reinforced Tissue Matrix In Hernia Repairs; Data To Be Presented At 2022 American Hernia Society (AHS) Meeting

August 4, 12:32 PM

24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year

TELA

1 minute read

Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings

By Vandana Singh

August 4, 12:18 PM

Organon & Co’s (NYSE:OGN) Q2 sales decreased 1% Y/Y to $1.59 billion, beating the consensus of $1.54 billion. The sales…

OGN

2 minute read

ChemoCentryx Shares Are Jumping 110% Thursday: Here’s Why

By Dylan Wechsler

August 4, 12:18 PM

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

AMGN

1 minute read

Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm

By Vandana Singh

August 4, 12:13 PM

Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists…

GILD

2 minute read

FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder

By Vandana Singh

August 4, 12:11 PM

The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…

BCRX

1 minute read

Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end

By Ragothaman Srinivasan

August 4, 12:03 PM

Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.

ATXS

1 minute read

FDA
News

Novavax Announces Initiation Of Phase 2b/3 Hummingbird Global Clinical Trial For Novavax COVID-19 Vaccine In Children Aged Six Months Through 11 Years

By Benzinga Newsdesk

August 4, 9:04 AM

Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3

NVAX

1 minute read

BioCryst Pharmaceuticals Says FDA Has Lifted Partial Clinical Hold On BCX9930 Program

By Bill Haddad

August 4, 7:58 AM

On August 4, 2022, the company announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under

BCRX

1 minute read

FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication

By Vandana Singh

August 4, 7:36 AM

Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.

TVTX